Electromyography (EMG) and Nerve Conduction Studies
Nerve conduction studies (NCS) and electromyography (EMG) are recognized electrophysiological techniques that play an important role in the diagnosis of neuromuscular diseases. Their early development is closely related to the discovery of electricity, this relationship has been clarified from the observation of the effect of applying electricity to animals and the discovery that nerves and muscles may be the source of electricity. The former paved the way for the practice of electrotherapy, and the latter provided a basis for electrodiagnosis. After years of extensive research, NCS and EMG have become pioneers in the field of clinical neurosubspecialty electrodiagnosis.
EMG and NCS are Painful Examinations
EMG and NCS are an unpleasant and sometimes painful examination. Pain reduces the patient's compliance and has a negative impact on the test results. Each factor induces positive emotional valence by acting as a distractor or affects pain perception through different sensory patterns. A numerical scale was used to evaluate pain. The pain levels of EMG and NCS for patients with different factors are ranked as follows:
Fig.1 Pyramid effect of pain degree of patients with EMG and NCS examinations and different factors.
Application of EMG and NCS in Diseases
- Coronavirus disease (COVID) -19 polyneuropathy
- Fibromyalgia (FM)
- Rehabilitation science
Three recent patients with sequelae of COVID-19 underwent NCS and EMG examinations. NCS showed partial or complete conduction blocks on several nerves, a slightly longer delay than the nerves, and rare or absent F waves, all these both indicate that SARS-COV-2 caused polyneuropathy. The short duration and low amplitude of the motor unit action potential with early full recruitment on interference pattern on EMG, typical for myopathy, suggest a direct action of COVID-19 on muscular fibers, especially in the lower limbs.
The results collected from the largest group of FM patients indicate that features of polyneuropathy, muscle attenuation, and chronic inflammatory degradation polyneuropathy (CIDP) are common in FM. EMG/NCS has detected large fibrosis (LFN) in FM patients, which may be a clinically useful tool for detecting LFN in FM and help to better understand the cause of this disorder.
The movement of the fingers is one of the main human movements by many scientists. The complexity analysis of EMG signals recorded by different actions through fractal analysis is very important for the research of rehabilitation science. Fractal theory can be applied to study the influence of other types of stimuli on the complexity of muscle response.
Fig.2 A sample of EMG signal in case of index finger flexion. (Namazi, 2019)
DPN is the most common long-term complication of patients with type 2 diabetes (T2DM), but the least recognized and understood. NCS and EMG are important non-invasive diagnostic methods used in the detection of diabetic peripheral neuropathy.
Early Development of EMG and NCS
- In 1771, Galvani proved that electrical stimulation of animal muscle tissue produces contraction, so the concept of animal electricity was born.
- In 1929, Adrian recorded the potential of a single motor unit by connecting concentric needle electrodes to amplifiers and speakers.
- In 1938, Denny Brown described the fascicular potential and separated it from fibrillation.
- In 1945, Larrabee measured the compound muscle action potentials of the health and injured nerves of war victims.
- In 1957, Lambert and Eaton described a new electrophysiological feature of myasthenia syndrome associated with lung cancer.
Creative Biolabs has advanced technology and a complete laboratory platform, which can provide you with professional analysis and strategies in the fields of neuroscience and biochemical technology. Please feel free to contact us if you are interested or have any questions.
Reference
- Namazi, H. Fractal-based classification of electromyography (EMG) signal in response to basic movements of the fingers. Fractals. 2019, 27(03): 1950037.

- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Anti-TNFα BBB Shuttle Antibody (NRZP-1022-ZP4105) (Cat#: NRZP-1022-ZP4105)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- iNeuMab™ Anti-EPHB2 Antibody (NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P517) (Cat#: NRP-0422-P517)
- iNeuMab™ Anti-GD2 Antibody (NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- iNeuMab™ Anti-Alpha Synuclein Antibody (NRP-0422-P614) (Cat#: NRP-0422-P614)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)